Healthcare stocks fell late Friday afternoon with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.
The iShares Biotechnology ETF (IBB) dropped 1.7%.
In corporate news, Novo Nordisk (NVO) shares fell past 9% after it said a late-stage trial of ziltivekimab was unable to reduce major adverse cardiovascular events, compared with a placebo.
AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected Q2 results. AbbVie shares were down 2%.
CareDx (CDNA) shares jumped past 14% a day after Q2 results beat market expectations and the company lifted its 2026 revenue guidance.
Replimune (REPL) shares surged 101% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.